SGI
CTKB icon

Summit Global Investments’s Cytek Biosciences CTKB Stock Holding History

Summit Global Investments’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-54,873
Closed -$220K – 480
2025
Q1 		$220K Buy
54,873
+18,684
+52% +$96.8K 0.02% 399
2024
Q4 		$235K Buy
+36,189
New +$216K 0.01% 485

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Summit Global Investments's CTKB Position: Q2 2025 in Review

Summit Global Investments sold out of Cytek Biosciences (CTKB) in Q2 2025, closing a stake of 54,873 shares — an estimated $220K sold.

Summit Global Investments first reported a position in CTKB in Q4 2024 and held it in 2 quarters. The position peaked at $235K in Q4 2024. 158 funds tracked by Wall St. Rank hold CTKB as of Q2 2025.

  • Summit Global Investments reported no remaining Cytek Biosciences position as of Q2 2025 after selling out during the quarter.
  • Summit Global Investments sold 54,873 Cytek Biosciences shares in Q2 2025, an estimated $220K.
  • Summit Global Investments first reported a position in Cytek Biosciences in Q4 2024 and held it in 2 quarters.
  • Summit Global Investments's Cytek Biosciences position peaked at $235K in Q4 2024.
  • 158 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2025.

Based on Summit Global Investments's 13F filing for Q2 2025, filed 12 Aug 2025.